Senses Disorder TRIZ Cases

A microemulsion with non-ionic surfactants and polysaccharides lubricates the ocular surface.

Pre-assembled ECM microparticles bypass slow cellular secretion, accelerating tissue repair and reducing scar formation.

Hydroxamic acid derivatives improve potency and bioavailability for cancer treatment.

Topical BTK inhibitors targeting Cys 481 resolve slow onset and burning associated with cyclosporine.

Interfering RNA silences TNFR1 mRNA expression to reduce TNF-alpha activity, blocking pathological neovascularization without causing localized retinal damage.

Muscarinic agonist and brimonidine composition extends near vision acuity while preventing ciliary muscle spasm.

Pyrrole-2-carboxamide derivatives selectively activate hepatic glucokinase to regulate glucose levels without inducing hypoglycemia.

Light-induced photoisomerization of azobenzene groups provides spatiotemporal control over HDAC inhibition, reducing off-target side effects.

A compounded pharmaceutical composition merges metformin, omega-3 fatty acids, and statins into a single dosage form.

Intrinsic angiogenesis inhibition via crosslinked serum albumin eliminates complex implant coatings while preventing tissue side effects.

Topical SRPK1 inhibitors promote anti-angiogenic VEGF isoforms to reduce excessive angiogenesis and adverse effects.

Floating culture of pluripotent stem cells with BMP and Wnt pathway modulators generates retinal pigment epithelial cell aggregates.

Formula I compounds modulate TGFβ activity to reduce fibrosis and tumor growth where existing therapies lack effective inhibition.

Segmented synthesis of unsymmetrical pyrrolobenzodiazepine dimers overcomes structural diversity limits in antitumor agents.

High-affinity monoclonal antibodies bind human poliovirus receptor to block TIGIT interaction and restore immune cell activity.

Engineering rAAV2-retro capsids resolves the contradiction between high retrograde transport efficiency and low transgene expression safety.

A stem cell concentrate combines mesenchymal stem cells, pericytes, and immature cells to deliver therapeutic potency in smaller quantities.

Composite hyaluronic acid gels reduce scleral fibrosis and eliminate antimetabolite toxicity while maintaining filtration function.

Piezo1 inhibitors block mechanosensing ion channels to protect retinal pigment epithelium cells from mechanical stress damage.

Non-covalent metal complex derivatives transport bio-available ions across the blood-brain barrier to treat neurodegenerative disorders.

Screening chemosensory receptors using computer modeling of the Venus flytrap domain to identify specific ligand modifiers.

Segmented polymer and silicone layers enable sustained drug release in sub-Tenon space, eliminating frequent injections and systemic side effects.

Targeting cold-inducible RNA-binding protein with inhibitors lowers inflammatory markers and tissue injury without broad immune suppression.

Combining diquafosol with polyvinylpyrrolidone and hydroxyethyl cellulose reduces instillation frequency while maintaining therapeutic effect.

Segmented placental bioreactors produce high-density exosome populations for therapeutic administration.

5-methyl substituted pyrimidine compounds inhibit JAK kinases to treat myeloproliferative disorders.

Viral vectors deliver RdCVF nucleic acids to retinal cells, eliminating repeated intraocular injections.

Segmenting differentiation stages to isolate specific progenitor cells, enabling three-dimensional organoid formation with functional secretion capability.

Anti-LOX-1 antibodies bind to LOX-1 receptors on immune cells to trigger intracellular signaling and surface marker upregulation.

Nano-micellar layers formed by nonionic surfactants reduce tear evaporation and dissolve lipid deposits on contact lenses.

High molecular weight albumin increases vitreous oncotic pressure, promoting aqueous efflux from retinal cysts to reduce edema without steroid side effects.

CRISPR nuclease degrades dominant-mutated rhodopsin mRNA while preserving functional allele expression.

Anthranilic acid amides improve solubility and stability while blocking VEGFR-2 to treat cancer.

Direct IL-1β neutralization overcomes frequent injection requirements of receptor antagonists, improving patient compliance.

Pure S-bucindolol increases nitric oxide production and reduces peroxynitrite formation to address reduced bioavailability in hypertension therapy.

Modified malonate derivatives overcome hydroxamic acid potency limits by inhibiting histone deacetylase to arrest neoplastic cell growth.

Peptide-modified AAV vectors overcome blood-retina barriers to target photoreceptors via intravenous delivery, avoiding invasive subretinal injections.

Triazole derivatives act as agonists or antagonists at GHS receptors, addressing the lack of specific biological activity in current compounds.

Dental pulp-derived stem cell culture supernatant restores lens tissue elasticity to correct myopia, astigmatism, and presbyopia without external intervention.

Segmenting hypervariable regions onto human frameworks reduces immunogenicity while maintaining high binding affinity for interleukin-17.

A coumestrol composition inhibits adipocyte differentiation and enhances immune cell proliferation.

Ultra-short double-stranded RNAs bind toll-like receptor-3 to block activation, preventing geographic atrophy and retinal damage in macular degeneration.

Aqueous tramadol ophthalmic composition provides effective ocular pain relief through dual opioid and non-opioid mechanisms.

Specific compounds modulate TRPM7 channels to resolve calcium overload and prevent neuronal death during ischemic injury.

Polyvinylpyrrolidone extends recombinant interferon contact time on the cornea, reducing treatment duration and complication rates.

Anti-human IL-17A monoclonal antibody blocks signaling pathways to reduce toxicity and side effects in autoimmune disease treatment.

Merging beta-2 agonist and muscarinic antagonist functions into one molecule reduces formulation complexity while maintaining therapeutic efficacy.

Targeting the ALK-1 pathway inhibits lymphatic vessel formation, reducing tumor metastasis without affecting blood vessel integrity.